Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Fennec Pharmaceuticals ( (TSE:FRX) ) is now available.
Fennec Pharmaceuticals has reached a settlement with Cipla Limited and Cipla USA over litigation related to Cipla’s bid to market a generic version of PEDMARK. Under the agreement, the case will be dismissed with each side covering its own costs, and Cipla is barred from launching a competing sodium thiosulfate product in the U.S. until September 1, 2033, subject to limited exceptions.
The accord preserves PEDMARK’s market exclusivity window in a niche but important pediatric oncology segment, supporting Fennec’s pricing power and revenue visibility in hearing-loss prevention linked to cisplatin therapy. With no prior preventive agents for this type of chemotherapy-induced ototoxicity and established Phase 3 data backing its safety and efficacy, PEDMARK remains well positioned in a specialized market where long-term hearing outcomes are a critical concern for young cancer patients and their caregivers.
The most recent analyst rating on (TSE:FRX) stock is a Buy with a C$13.00 price target. To see the full list of analyst forecasts on Fennec Pharmaceuticals stock, see the TSE:FRX Stock Forecast page.
Spark’s Take on FRX Stock
According to Spark, TipRanks’ AI Analyst, FRX is a Neutral.
The score is primarily held back by mixed financial performance (TTM losses, renewed cash burn, and weak capitalization in the provided statements) and bearish technical signals (below key moving averages with negative MACD). Positive corporate events provide an offset through improved commercial momentum and clinical/financing progress, but not enough to outweigh the current financial and trend risks.
To see Spark’s full report on FRX stock, click here.
More about Fennec Pharmaceuticals
Fennec Pharmaceuticals is a specialty pharmaceutical company focused on pediatric oncology supportive care. Its lead product, PEDMARK, is the first and only FDA-approved sodium thiosulfate injection to reduce the risk of cisplatin-induced ototoxicity in pediatric patients with localized, non-metastatic solid tumors, targeting a significant unmet need among children and adolescents receiving platinum-based chemotherapy in the U.S.
YTD Price Performance: -0.42%
Average Trading Volume: 811
Technical Sentiment Signal: Buy
Current Market Cap: C$360.3M
For detailed information about FRX stock, go to TipRanks’ Stock Analysis page.